Sino Biopharmaceutical Forecast, price target & analysts
Sino Biopharmaceutical Target price 2025 - Analyst rating & recommendation
Sino Biopharmaceutical Classifications & Recommendation:
Sino Biopharmaceutical Price Target
| Target Price | HKD4.18 |
| Price | HKD3.22 |
| Potential |
29.86%
register free of charge
|
| Number of Estimates | 8 |
|
8 Analysts have issued a price target Sino Biopharmaceutical 2026 .
The average Sino Biopharmaceutical target price is HKD4.18.
This is
29.86%
register free of charge
HKD5.04
56.59%
register free of charge
HKD3.01
6.39%
register free of charge
|
|
| A rating was issued by 11 analysts: 10 Analysts recommend Sino Biopharmaceutical to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Sino Biopharmaceutical stock has an average upside potential 2026 of
29.86%
register free of charge
|
Sales and Margin forecast 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Revenue Billion HKD | 28.95 | 31.04 |
| 4.34% | 7.21% | |
| EBITDA Margin | 25.87% | 26.34% |
| 1.13% | 1.83% | |
| Net Margin | 8.87% | 12.44% |
| 8.53% | 40.29% |
8 Analysts have issued a sales forecast Sino Biopharmaceutical 2024 . The average Sino Biopharmaceutical sales estimate is
This results in the following potential growth metrics:
7 Analysts have issued an Sino Biopharmaceutical EBITDA forecast 2024. The average Sino Biopharmaceutical EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
5 Sino Biopharmaceutical Analysts have issued a net profit forecast 2024. The average Sino Biopharmaceutical net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Earnings Per Share HKD | 0.14 | 0.21 |
| 12.50% | 50.00% | |
| P/E | 16.33 | |
| EV/Sales | 2.23 |
5 Analysts have issued a Sino Biopharmaceutical forecast for earnings per share. The average Sino Biopharmaceutical <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Sino Biopharmaceutical stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Sino Biopharmaceutical...
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
